Similar articles

• Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.

  Kaden J, Strobelt V, May G. Kaden J, et al. Transplant Proc. 1998 Dec;30(8):4011-4. doi: 10.1016/s0041-1345(98)01322-0. Transplant Proc. 1998. PMID: 9865279 No abstract available.
• Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center.

  Schneeberger H, Zanker B, Hillebrand G, Illner WD, Rothenpieler U, Land W. Schneeberger H, et al. Transplant Proc. 1998 Jun;30(4):1598-9. doi: 10.1016/s0041-1345(98)00366-2. Transplant Proc. 1998. PMID: 9636642 No abstract available.
• Quadruple immunotherapy will promise excellent graft survival in cadaveric renal transplants using cardiac arrest donor grafts.

  Hoshinaga K, Shiroki R, Higuchi T, Horiba Y, Yanaoka M, Naide Y. Hoshinaga K, et al. Transplant Proc. 1996 Jun;28(3):1591-3. Transplant Proc. 1996. PMID: 8658798 No abstract available.
• Impact of delayed graft function on cadaveric kidney transplant outcome.

  Gentil MA, Alcaide MP, Algarra GR, Pereira P, Toro J, González-Roncero F, López M, Bernal G, Mateos J. Gentil MA, et al. Transplant Proc. 2003 Mar;35(2):689-91. doi: 10.1016/s0041-1345(03)00048-4. Transplant Proc. 2003. PMID: 12644095 No abstract available.
• Intensive care and immediate follow-up of children after renal transplantation.

  Seikaly MG, Sanjad SA. Seikaly MG, et al. Transplant Proc. 2001 Aug;33(5):2821-4. doi: 10.1016/s0041-1345(01)02204-7. Transplant Proc. 2001. PMID: 11498173 Review. No abstract available.